Impact of Chemotherapy on Urinary Biomarkers and Non-Invasive Urodynamics in Children

Launched by UNIVERSITY OF COLORADO, DENVER · Aug 5, 2021

Keywords

ClinConnect Summary

This clinical trial is looking at how two specific cancer treatments, vincristine and doxorubicin, affect bladder function and urine quality in children who have survived cancer. The study aims to understand if these treatments can lead to bladder problems in the long term. Researchers want to include children aged 5 to 13 years who have completed their chemotherapy at least a year ago. However, those with certain conditions, like pelvic tumors or bladder issues before treatment, won't be eligible to participate.

If your child qualifies and joins the study, they will undergo tests to assess their bladder function and analyze their urine. This will help scientists learn more about the side effects of these chemotherapy drugs and how they impact young cancer survivors. It's an important step toward ensuring better long-term health for children who have battled cancer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Children aged 5-13 years old
• • A history of cancer
• • Treatment with a chemotherapy regimen including VCR and/or DOX
• • Completion of chemotherapy at least one year prior to study enrollment and survey completion.
• Exclusion Criteria:
• * Patients with a:
• • Primary pelvic tumor
• • Pelvic irradiation
• • Pre-existing bladder/bowel dysfunction
• • Spinal defects
• • Neurologic disorder
• • Neuro-oncologic tumor or brain metastasis
• • Cyclophosphamide or ifosfamide therapy